Table 1 Open in new tab Demographic and...

Characteristics	N	(%)
Age (year), mean ± SD	67.7 ± 10.7 (range: 36–87; median: 69)
Sex	Male	54	50.1
Education	≥High school	79	74.5
Marital status	Married	74	69.8
Job	Employed (full-time/part-time)	39	36.8
Type of myeloma	IgG	59	55.6
	IgA	23	21.7
	Light chain disease	23	21.7
	Others	1	0.9
International Staging System score	I	17	16.0
	II	50	47.2
	III	39	36.8
Performance status	0	31	29.2
(ECOG)	1	43	40.6
	2	11	10.4
	3	14	13.2
	4	6	5.7
	Missing	1	0.9
Intensity of received treatments at T3^{a b}	Chemotherapy only	48	58.5
	Bortezomib-based	26	31.7
	Lenalidomide-based	14	17.1
	+Daratumumab	5	6.1
	Other	8	9.8
	HDC/ASCT	34	41.5
Chemotherapy at T3^b	Chemotherapy free (remission)	49	59.8
	Relapsed or undergoing chemotherapy	33	40.2
Number of prior MM therapies within 1 year	1	63	76.8
	2	17	20.7
	3	2	2.4

Characteristics	N	(%)
Age (year), mean ± SD	67.7 ± 10.7 (range: 36–87; median: 69)
Sex	Male	54	50.1
Education	≥High school	79	74.5
Marital status	Married	74	69.8
Job	Employed (full-time/part-time)	39	36.8
Type of myeloma	IgG	59	55.6
	IgA	23	21.7
	Light chain disease	23	21.7
	Others	1	0.9
International Staging System score	I	17	16.0
	II	50	47.2
	III	39	36.8
Performance status	0	31	29.2
(ECOG)	1	43	40.6
	2	11	10.4
	3	14	13.2
	4	6	5.7
	Missing	1	0.9
Intensity of received treatments at T3^{a b}	Chemotherapy only	48	58.5
	Bortezomib-based	26	31.7
	Lenalidomide-based	14	17.1
	+Daratumumab	5	6.1
	Other	8	9.8
	HDC/ASCT	34	41.5
Chemotherapy at T3^b	Chemotherapy free (remission)	49	59.8
	Relapsed or undergoing chemotherapy	33	40.2
Number of prior MM therapies within 1 year	1	63	76.8
	2	17	20.7
	3	2	2.4

Table 1

Demographic and clinical characteristics of patients (N = 106)

Characteristics		N	(%)
Age (year), mean ± SD	67.7 ± 10.7 (range: 36–87; median: 69)
Sex	Male	54	50.1
Education	≥High school	79	74.5
Marital status	Married	74	69.8
Job	Employed (full-time/part-time)	39	36.8
Type of myeloma	IgG	59	55.6
	IgA	23	21.7
	Light chain disease	23	21.7
	Others	1	0.9
International Staging System score	I	17	16.0
	II	50	47.2
	III	39	36.8
Performance status	0	31	29.2
(ECOG)	1	43	40.6
	2	11	10.4
	3	14	13.2
	4	6	5.7
	Missing	1	0.9
Intensity of received treatments at T3^{a b}	Chemotherapy only	48	58.5
	Bortezomib-based	26	31.7
	Lenalidomide-based	14	17.1
	+Daratumumab	5	6.1
	Other	8	9.8
	HDC/ASCT	34	41.5
Chemotherapy at T3^b	Chemotherapy free (remission)	49	59.8
	Relapsed or undergoing chemotherapy	33	40.2
Number of prior MM therapies within 1 year	1	63	76.8
	2	17	20.7
	3	2	2.4

Characteristics		N	(%)
Age (year), mean ± SD	67.7 ± 10.7 (range: 36–87; median: 69)
Sex	Male	54	50.1
Education	≥High school	79	74.5
Marital status	Married	74	69.8
Job	Employed (full-time/part-time)	39	36.8
Type of myeloma	IgG	59	55.6
	IgA	23	21.7
	Light chain disease	23	21.7
	Others	1	0.9
International Staging System score	I	17	16.0
	II	50	47.2
	III	39	36.8
Performance status	0	31	29.2
(ECOG)	1	43	40.6
	2	11	10.4
	3	14	13.2
	4	6	5.7
	Missing	1	0.9
Intensity of received treatments at T3^{a b}	Chemotherapy only	48	58.5
	Bortezomib-based	26	31.7
	Lenalidomide-based	14	17.1
	+Daratumumab	5	6.1
	Other	8	9.8
	HDC/ASCT	34	41.5
Chemotherapy at T3^b	Chemotherapy free (remission)	49	59.8
	Relapsed or undergoing chemotherapy	33	40.2
Number of prior MM therapies within 1 year	1	63	76.8
	2	17	20.7
	3	2	2.4

Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; HDC/ASCT, high-dose melphalan/autologous stem cell transplantation; Ig, immunoglobin.

^a88 patients completed the T3 survey.

^bTreatment status data for 6 patients at T3 were missing.

This Feature Is Available To Subscribers Only